View in EDS HTML Full Text PDF Full Text

Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders.

Saved in:
Bibliographic Details
Title: Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders.
Authors: Williams, Arthur Robin, Barbieri, Vincent, Mishlen, Kaitlyn, Levin, Frances R., Nunes, Edward V., Mariani, John J., Bisaga, Adam
Source: American Journal on Addictions. Jun2017, Vol. 26 Issue 4, p319-325. 7p.
Subjects: Naltrexone, Drug abuse treatment, Opioid abuse, Substance abuse treatment, Drug side effects, Patient compliance, Therapeutics, Substance abuse & psychology, Narcotic antagonists, Controlled release preparations, Drugs, Health attitudes, Longitudinal method, Substance abuse
Abstract: Background and Objectives: Extended-release naltrexone (XR-NTX) is FDA-approved to prevent relapse in patients with Opioid Use Disorder. However little is known about long-term use among community-based outpatients.Methods: Retrospective chart review and long-term follow-up survey among individuals (N = 168) who entered an outpatient XR-NTX trial between 2011 and 2015, during which participants were offered three monthly injections of XR-NTX at no cost. The survey consisted of 35 questions covering a total of four domains: (1) substance use; (2) treatment continuation; (3) barriers; and (4) attitudes.Results: Fifty-seven respondents were successfully surveyed, including 50% of those initially receiving all three XR-NTX injections ("study completers") in the parent study. Study completion was associated with superior outcomes and less likely relapse (defined as daily use), with a much greater time to relapse despite higher rates of concurrent non-opioid substance use. However the majority of participants discontinued treatment with XR-NTX at study completion, largely due to attitudes of "feeling cured" and "wanting to do it on my own" rather than external barriers such as cost or side effects.Conclusion: Patients who initiate treatment with XR-NTX might benefit from anticipatory guidance and motivational techniques to encourage long-term adherence as many will experience internal barriers to continuation. Our findings are reassuring that few patients experience side effects or adverse events complicating the effectiveness or safety of long-term use of XR-NTX.Scientific Significance: Among outpatients who successfully receive 3 monthly XR-NTX injections, many will prematurely discontinue treatment due to internal attitudes, such as "feeling cured." (Am J Addict 2017;26:319-325). [ABSTRACT FROM AUTHOR]
Copyright of American Journal on Addictions is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 122988300
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Williams%2C+Arthur+Robin%22">Williams, Arthur Robin</searchLink><br /><searchLink fieldCode="AR" term="%22Barbieri%2C+Vincent%22">Barbieri, Vincent</searchLink><br /><searchLink fieldCode="AR" term="%22Mishlen%2C+Kaitlyn%22">Mishlen, Kaitlyn</searchLink><br /><searchLink fieldCode="AR" term="%22Levin%2C+Frances+R%2E%22">Levin, Frances R.</searchLink><br /><searchLink fieldCode="AR" term="%22Nunes%2C+Edward+V%2E%22">Nunes, Edward V.</searchLink><br /><searchLink fieldCode="AR" term="%22Mariani%2C+John+J%2E%22">Mariani, John J.</searchLink><br /><searchLink fieldCode="AR" term="%22Bisaga%2C+Adam%22">Bisaga, Adam</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22American+Journal+on+Addictions%22">American Journal on Addictions</searchLink>. Jun2017, Vol. 26 Issue 4, p319-325. 7p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Naltrexone%22">Naltrexone</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+abuse+treatment%22">Drug abuse treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Opioid+abuse%22">Opioid abuse</searchLink><br /><searchLink fieldCode="DE" term="%22Substance+abuse+treatment%22">Substance abuse treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+side+effects%22">Drug side effects</searchLink><br /><searchLink fieldCode="DE" term="%22Patient+compliance%22">Patient compliance</searchLink><br /><searchLink fieldCode="DE" term="%22Therapeutics%22">Therapeutics</searchLink><br /><searchLink fieldCode="DE" term="%22Substance+abuse+%26+psychology%22">Substance abuse & psychology</searchLink><br /><searchLink fieldCode="DE" term="%22Narcotic+antagonists%22">Narcotic antagonists</searchLink><br /><searchLink fieldCode="DE" term="%22Controlled+release+preparations%22">Controlled release preparations</searchLink><br /><searchLink fieldCode="DE" term="%22Drugs%22">Drugs</searchLink><br /><searchLink fieldCode="DE" term="%22Health+attitudes%22">Health attitudes</searchLink><br /><searchLink fieldCode="DE" term="%22Longitudinal+method%22">Longitudinal method</searchLink><br /><searchLink fieldCode="DE" term="%22Substance+abuse%22">Substance abuse</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background and Objectives: </bold>Extended-release naltrexone (XR-NTX) is FDA-approved to prevent relapse in patients with Opioid Use Disorder. However little is known about long-term use among community-based outpatients.<bold>Methods: </bold>Retrospective chart review and long-term follow-up survey among individuals (N = 168) who entered an outpatient XR-NTX trial between 2011 and 2015, during which participants were offered three monthly injections of XR-NTX at no cost. The survey consisted of 35 questions covering a total of four domains: (1) substance use; (2) treatment continuation; (3) barriers; and (4) attitudes.<bold>Results: </bold>Fifty-seven respondents were successfully surveyed, including 50% of those initially receiving all three XR-NTX injections ("study completers") in the parent study. Study completion was associated with superior outcomes and less likely relapse (defined as daily use), with a much greater time to relapse despite higher rates of concurrent non-opioid substance use. However the majority of participants discontinued treatment with XR-NTX at study completion, largely due to attitudes of "feeling cured" and "wanting to do it on my own" rather than external barriers such as cost or side effects.<bold>Conclusion: </bold>Patients who initiate treatment with XR-NTX might benefit from anticipatory guidance and motivational techniques to encourage long-term adherence as many will experience internal barriers to continuation. Our findings are reassuring that few patients experience side effects or adverse events complicating the effectiveness or safety of long-term use of XR-NTX.<bold>Scientific Significance: </bold>Among outpatients who successfully receive 3 monthly XR-NTX injections, many will prematurely discontinue treatment due to internal attitudes, such as "feeling cured." (Am J Addict 2017;26:319-325). [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of American Journal on Addictions is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=122988300
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/ajad.12527
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 7
        StartPage: 319
    Subjects:
      – SubjectFull: Naltrexone
        Type: general
      – SubjectFull: Drug abuse treatment
        Type: general
      – SubjectFull: Opioid abuse
        Type: general
      – SubjectFull: Substance abuse treatment
        Type: general
      – SubjectFull: Drug side effects
        Type: general
      – SubjectFull: Patient compliance
        Type: general
      – SubjectFull: Therapeutics
        Type: general
      – SubjectFull: Substance abuse & psychology
        Type: general
      – SubjectFull: Narcotic antagonists
        Type: general
      – SubjectFull: Controlled release preparations
        Type: general
      – SubjectFull: Drugs
        Type: general
      – SubjectFull: Health attitudes
        Type: general
      – SubjectFull: Longitudinal method
        Type: general
      – SubjectFull: Substance abuse
        Type: general
    Titles:
      – TitleFull: Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Williams, Arthur Robin
      – PersonEntity:
          Name:
            NameFull: Barbieri, Vincent
      – PersonEntity:
          Name:
            NameFull: Mishlen, Kaitlyn
      – PersonEntity:
          Name:
            NameFull: Levin, Frances R.
      – PersonEntity:
          Name:
            NameFull: Nunes, Edward V.
      – PersonEntity:
          Name:
            NameFull: Mariani, John J.
      – PersonEntity:
          Name:
            NameFull: Bisaga, Adam
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: Jun2017
              Type: published
              Y: 2017
          Identifiers:
            – Type: issn-print
              Value: 10550496
          Numbering:
            – Type: volume
              Value: 26
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: American Journal on Addictions
              Type: main
ResultId 1